MedImmune, NGM ally to develop drugs for obesity, diabetes

06/18/2013 | PharmaTimes (U.K.)

AstraZeneca's MedImmune unit and NGM Biopharmaceuticals will collaborate in the discovery and development of the latter's enteroendocrine cell program for the treatment of obesity and type 2 diabetes. The firms intend to develop first-in-class peptide and antibody treatments based on the EEC hormones. The deal entitles NGM to upfront payment, research funding, milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT